Stock Scorecard
Stock Summary for TG Therapeutics Inc (TGTX) - $57.12 as of 7/13/2026 3:44:21 PM EST
Total Score
14 out of 30
Safety Score
56 out of 100
Currently on the following lists
None
Tim's Recommendation
Possible Buy
Growth List Algorithm Criteria for TGTX
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for TGTX
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for TGTX
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for TGTX
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for TGTX (56 out of 100)
| Stock Price Rating (Max of 10) | 9 |
| Historical Stock Price Rating (Max of 10) | 5 |
| Stock Price Trend (Max of 10) | 10 |
| Book Value (Max of 10) | 3 |
| Book Value to Price (Max of 10) | 0 |
| Analyst Buy Ratings (Max of 5) | 5 |
| Analyst Strong Buy Ratings (Max of 5) | 3 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 4 |
| Trading Volume (Max of 10) | 9 |
| Price to Earnings (Max of 10) | 8 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | 0 |
Latest News for for TGTX
Financial Details for TGTX
Company Overview |
|
|---|---|
| Ticker | TGTX |
| Company Name | TG Therapeutics Inc |
| Country | USA |
| Description | TG Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company is headquartered in New York, New York. |
| Sector Name | HEALTHCARE |
| Industry Name | BIOTECHNOLOGY |
| Most Recent Quarter | 3/31/2026 |
| Next Earnings Date | 8/3/2026 |
Stock Price History |
|
| Last Day Price | 57.12 |
| Price 4 Years Ago | 11.83 |
| Last Day Price Updated | 7/13/2026 3:44:21 PM EST |
| Last Day Volume | 1,230,394 |
| Average Daily Volume | 2,715,995 |
| 52-Week High | 59.30 |
| 52-Week Low | 25.28 |
| Last Price to 52 Week Low | 125.95% |
Valuation Measures |
|
| Trailing PE | 20.02 |
| Industry PE | 98.16 |
| Sector PE | 99.45 |
| 5-Year Average PE | 100.30 |
| Free Cash Flow Ratio | 19.76 |
| Industry Free Cash Flow Ratio | 26.56 |
| Sector Free Cash Flow Ratio | 28.52 |
| Current Ratio Most Recent Quarter | 5.81 |
| Total Cash Per Share | 2.89 |
| Book Value Per Share Most Recent Quarter | 4.11 |
| Price to Book Ratio | 15.03 |
| Industry Price to Book Ratio | 12.29 |
| Sector Price to Book Ratio | 13.70 |
| Price to Sales Ratio Twelve Trailing Months | 12.91 |
| Industry Price to Sales Ratio Twelve Trailing Months | 10.58 |
| Sector Price to Sales Ratio Twelve Trailing Months | 27.48 |
| Analyst Buy Ratings | 6 |
| Analyst Strong Buy Ratings | 1 |
Share Statistics |
|
| Total Shares Outstanding | 153,084,000 |
| Market Capitalization | 8,744,158,080 |
| Institutional Ownership | 70.25% |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.72% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 300.00% |
| Annual Earnings Growth | 1,812.41% |
| Reported EPS 12 Trailing Months | 2.95 |
| Reported EPS Past Year | 0.18 |
| Reported EPS Prior Year | 0.50 |
| Net Income Twelve Trailing Months | 461,896,000 |
| Net Income Past Year | 447,179,000 |
| Net Income Prior Year | 23,383,000 |
| Quarterly Revenue Growth YOY | 69.60% |
| 5-Year Revenue Growth | 426.73% |
| Operating Margin Twelve Trailing Months | 17.00% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 442,209,000 |
| Total Cash Past Year | 79,148,000 |
| Total Cash Prior Year | 179,894,000 |
| Net Cash Position Most Recent Quarter | -302,931,000 |
| Net Cash Position Past Year | -166,497,000 |
| Long Term Debt Past Year | 245,645,000 |
| Long Term Debt Prior Year | 244,429,000 |
| Total Debt Most Recent Quarter | 745,140,000 |
| Equity to Debt Ratio Past Year | 0.73 |
| Equity to Debt Ratio Most Recent Quarter | 0.44 |
| Total Stockholder Equity Past Year | 648,020,000 |
| Total Stockholder Equity Prior Year | 222,364,000 |
| Total Stockholder Equity Most Recent Quarter | 583,131,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | -14,191,000 |
| Free Cash Flow Per Share Twelve Trailing Months | -0.09 |
| Free Cash Flow Past Year | -24,986,000 |
| Free Cash Flow Prior Year | -40,562,000 |
Options |
|
| Put/Call Ratio | 1.02 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | 3.71 |
| MACD Signal | 3.73 |
| 20-Day Bollinger Lower Band | 20.94 |
| 20-Day Bollinger Middle Band | 39.62 |
| 20-Day Bollinger Upper Band | 58.30 |
| Beta | 1.60 |
| RSI | 75.42 |
| 50-Day SMA | 34.20 |
| 150-Day SMA | 0.00 |
| 200-Day SMA | 0.00 |
System |
|
| Modified | 7/11/2026 9:14:10 AM EST |